Literature DB >> 10998527

Nociceptin/orphanin FQ receptor ligands.

G Calo'1, R Bigoni, A Rizzi, R Guerrini, S Salvadori, D Regoli.   

Abstract

Nociceptin (NC), alias Orphanin FQ (OFQ) is a heptadecapeptide structurally related to opioid peptides, especially Dynorphin A, which, however, does not interact with classic opioid receptors. NC selectively activates its own receptor (OP(4)), which has been shown to be insensitive to the naturally occurring opioid peptides as well as to a large number of non-peptide opioid receptor ligands, including naloxone. Thus, the NC/OP(4) system represents a new peptide-based signaling pathway, which is pharmacologically distinct from the opioid systems. The pharmacological tools available for investigating NC actions are at present rather limited and include: 1) peptide ligands obtained from structure activity studies performed using NC(1-13)NH(2) as a template or discovered by screening peptide combinatorial libraries; 2) nonpeptide ligands that are either molecules already known to interact with classic opioid receptors or novel molecules designed and synthesized as selective ligands of the OP(4) receptor. In the present paper the functional data obtained from both in vitro and in vivo studies with each relevant OP(4) receptor ligand will be analyzed and discussed comparing the advantages and disadvantages of each molecule. We hope that the present work will aid investigators, working in the NC/OP(4) field, in the choice of the pharmacological tools suitable for their experiments.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10998527     DOI: 10.1016/s0196-9781(00)00230-8

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  22 in total

1.  Nociceptin/Orphanin FQ Inhibits the Survival and Axon Growth of Midbrain Dopaminergic Neurons Through a p38-MAPK Dependent Mechanism.

Authors:  Louise M Collins; Giorgia Dal Bo; Mariangela Calcagno; Jimena Monzón-Sandoval; Aideen M Sullivan; Humberto Gutierrez; Michele Morari; Gerard W O'Keeffe
Journal:  Mol Neurobiol       Date:  2015-12-21       Impact factor: 5.590

2.  Binding of GTPgamma[35S] is regulated by GDP and receptor activation. Studies with the nociceptin/orphanin FQ receptor.

Authors:  John McDonald; David G Lambert
Journal:  Br J Pharmacol       Date:  2010-02-10       Impact factor: 8.739

3.  Nociceptin/orphanin FQ presynaptically decreases GABAergic transmission and blocks the ethanol-induced increase of GABA release in central amygdala.

Authors:  Marisa Roberto; George R Siggins
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-20       Impact factor: 11.205

4.  Brain opioid and nociceptin receptors are involved in regulation of bombesin-induced activation of central sympatho-adrenomedullary outflow in the rat.

Authors:  Toshio Yawata; Youichirou Higashi; Takahiro Shimizu; Shogo Shimizu; Kumiko Nakamura; Keisuke Taniuchi; Tetsuya Ueba; Motoaki Saito
Journal:  Mol Cell Biochem       Date:  2015-10-01       Impact factor: 3.396

5.  Pharmacological characterization of the novel nociceptin/orphanin FQ receptor ligand, ZP120: in vitro and in vivo studies in mice.

Authors:  Anna Rizzi; Daniela Rizzi; Giuliano Marzola; Domenico Regoli; Bjarne Due Larsen; Jorgen Soberg Petersen; Girolamo Calo'
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

6.  Pharmacological profile of the cyclic nociceptin/orphanin FQ analogues c[Cys10,14]N/OFQ(1-14)NH2 and c[Nphe1,Cys10,14]N/OFQ(1-14)NH2.

Authors:  M Kitayama; T A Barnes; G Carra; J McDonald; G Calo; R Guerrini; D J Rowbotham; G Smith; D G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-04       Impact factor: 3.000

Review 7.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

8.  Biostable aptamers with antagonistic properties to the neuropeptide nociceptin/orphanin FQ.

Authors:  Dirk Faulhammer; Bernd Eschgfäller; Sandra Stark; Petra Burgstaller; Werner Englberger; Jeannette Erfurth; Frank Kleinjung; Johanna Rupp; Sebastian Dan Vulcu; Werner Schröder; Stefan Vonhoff; Hermann Nawrath; Clemens Gillen; Sven Klussmann
Journal:  RNA       Date:  2004-03       Impact factor: 4.942

9.  Partial agonist behaviour depends upon the level of nociceptin/orphanin FQ receptor expression: studies using the ecdysone-inducible mammalian expression system.

Authors:  J McDonald; T A Barnes; H Okawa; J Williams; G Calo'; D J Rowbotham; D G Lambert
Journal:  Br J Pharmacol       Date:  2003-08-11       Impact factor: 8.739

Review 10.  Antidepressant- and anxiolytic-like effects of nociceptin/orphanin FQ receptor ligands.

Authors:  Elaine C Gavioli; Girolamo Calo'
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-02-21       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.